Sanofi links with Spanish research institute on rare diseases

The Center for Genomic Regulation (Centre de Regulacio Genomica - CRG), a biomedical research institute of excellence supported by the Catalan government and the Spanish Ministry of Science and Innovation, and French drug major Sanofi (Euronext: SAN) have entered into a research collaboration on shared research programs using state-of-the-art experimental platforms and computational and bioinformatics approaches, in the field of computational biology, medical genetics and epigenetics, with special emphasis in genetic and rare diseases.

This strategic partnership is based on the cross-fertilization of R&D know-how from both sides, including scientific resources, structures and information, technical equipment and human talent.

"Research cannot remain distanced from the needs of society. Biology is getting ever closer to medicine and an institute like the Centre for Genomic Regulation must ensure that its research has a positive impact on human health and national economies. Yet, we cannot do this alone and we need to collaborate with strategic partners for this purpose”, said Luis Serrano, director of the CGR, adding: “Through this agreement Sanofi will have increased access to globally cutting-edge research and the CRG will be linked to a major company that can ensure the translation of research into real-life solutions for patients."